UPDATED: Oxford and Novavax tout 75%+ efficacy for malaria vaccine, besting GlaxoSmithKline in long hunt to inoculate against the deadly parasite
Novavax and Oxford’s Jenner Institute have spent the last 16 months making headlines for their Covid-19 vaccines. But, quietly, the two groups have also spent that time working on an inoculation for a different deadly pathogen: malaria.
That effort has now brought its first major result. In The Lancet Friday, investigators reported that their experimental malaria vaccine was 77% effective at preventing malaria in a trial of 450 children in Burkina Faso.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.